Influence of clofarabine on transcriptional activity of PTEN, APC, RARB2, ZAP70 genes in K562 cells

Anticancer Research

Volumn 30, Issue 11, 2010, Pages 4601-4606

  Majda, Katarzyna ^a   Kaufman Szymczyk, Agnieszka ^a   Lubecka Pietruszewska, Katarzyna ^a   Bednarek, Andrzej ^a   Fabianowska Majewska, Krystyna ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Adenosine analogue; APC; Clofarabine; Epigenetic; Promoter methylation; PTEN; RARB2; ZAP70

Indexed keywords

APC PROTEIN; CLOFARABINE; DNA METHYLTRANSFERASE 1; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN; PROTEIN KINASE ZAP 70; RARB2 PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CELL STRAIN K 562; DNA METHYLATION; DRUG EFFECT; EPIGENETICS; GENE EXPRESSION; GENETIC REGULATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; TRANSCRIPTION INITIATION;

ADENINE NUCLEOTIDES; ADENOMATOUS POLYPOSIS COLI PROTEIN; ANTINEOPLASTIC AGENTS; ARABINONUCLEOSIDES; BLOTTING, WESTERN; CELL PROLIFERATION; CPG ISLANDS; DNA METHYLATION; DNA, NEOPLASM; DOWN-REGULATION; EPIGENOMICS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; K562 CELLS; POLYMERASE CHAIN REACTION; PTEN PHOSPHOHYDROLASE; RECEPTORS, RETINOIC ACID; RNA, MESSENGER; RNA, NEOPLASM; ZAP-70 PROTEIN-TYROSINE KINASE;

EID: 78650244965     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Beesley AH, Palmer M-L, Ford J, Weller RE, Cummings AJ, Freitas JR, Firth MJ, Perera KU, de Klerk NH and Kees U: In vitro cytotoxicity of nelarabine, clofarabine and flavopiridol in paediatric acute lymphoblastic leukaemia. Br J Haematol 137: 109-116, 2007.
2. Wyczechowska D and Fabianowska-Majewska K: The effects of cladribine and fludarabine on DNA methylation in K562 cells. Biochem Pharmacol 65: 219-225, 2003. (Pubitemid 36015824)
3. Montgomery JA, Shortnacy-Fowler AT, Clayton SD, Riordan JM and Secrist III JA: Synthesis and biologic activity of 2′-fluoro-2-halo derivatives of 9-beta-D-arabinofuranosyladenine. J Med Chem 35: 397-401, 1992.
4. Kantarjian HM, Gandhi V, Kozuch P, Faderl S, Giles F, Cortes J, O'Brien S, Ibrahim N, Khuri F, Du M, Rios MB, Jeha S, McLaughlin P, Plunkett W and Keating M: Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J Clin Oncol 21: 1167-1173, 2003. (Pubitemid 46594149)
5. Kantarjian HM, Erba HP, Claxton D, Arellano M, Lyons RM, Kovascovics T, Gabrilove J, Craig M, Douer D, Maris M, Petersdorf S and Shami PJ: Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors. J Clin Oncol 28: 549-555, 2010.
6. Faderl S, Ferrajoli A, Wierda W, Huang X, Verstovsek S, Ravandi F, Estrov Z, Borthakur G, Kwari M and Kantarjian HM: Clofarabine combinations as acute myeloid leukemia salvage therapy. Cancer 113: 2090-2096, 2008.
7. Burnett AK and Mohite U: Treatment of older patients with acute myeloid leukemia - new agents. Semin Hematol 43: 96-106, 2006.
8. Karp JE, Ricklis RM, Balakrishnan K, Briel J, Greer J, Gore SD, Smith BD, McDevitt MA, Carraway H, Levis MJ and Gandhi V: A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias. Blood 110: 1762-1769, 2007. (Pubitemid 47443886)
9. Xie C and Plunkett W: Metabolism and actions of 2-chloro-9-(2-deoxy-2- fluoro-beta-D-arabinofuranosyl)-adenine in human lymphoblastoid cells. Cancer Res 55: 2847-2852, 1995.
10. Xie KC and Plunkett W: Deoxynucleotide pool depletion and sustained inhibition of ribonucleotide reductase and DNA synthesis after treatment of human lymphoblastoid cells with 2-chloro-9-(2-deoxy-2-fluoro-beta-D- arabinofuranosyl) adenine. Cancer Res 56: 3030-3037, 1996. (Pubitemid 26200765)
11. Genini D, Adachi S, Chao Q, Rose DW, Carrera CJ, Cottam HB, Carson DA and Leoni LM: Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria. Blood 96: 3537-3543, 2000.
12. Chen LS, Plunkett W and Gandhi V: Polyadenylation inhibition by the triphosphates of deoxyadenosine analogues. Leuk Res 32: 1573-1581, 2008.
13. Zhang Y, Shahriar M, Zhang J, Ahmed SU and Lim SH: Clofarabine induces hypomethylation of DNA and expression of cancer-testis antigens. Leuk Res 33: 1678-1683, 2009.
14. Krawczyk B and Fabianowska-Majewska K: Alteration of DNA methylation status in K562 and MCF-7 cancer cell lines by nucleoside analogues. Nucleos Nucleot Nucleic Acids 25: 1029-1032, 2006.
15. Virmani AK, Muller C, Rathi A, Zoechbauer-Mueller S, Mathis M and Gazdar AF: Aberrant methylation during cervical carcinogenesis. Clin Cancer Res 7: 584-589, 2001.
16. Krawczyk B, Rudnicka K and Fabianowska-Majewska K: The effects of nucleoside analogues on promoter methylation of selected tumor suppressor genes in MCF-7 and MDA-MB-231 breast cancer cell lines. Nucleos Nucleot Nucleic Acids 26: 1043-1046, 2007.
17. Zysman MA, Chapman WB and Bapat B: Consideration when analysing the methylation status of PTEN tumor suppressor gene. Am J Pathol 160: 795-800, 2002.
18. Buckingham L, Penfield Faber L, Kim A, Liptay M, Barger C, Basu S, Fidler M, Walters K, Bonomi P and Coon J: PTEN, RASSF1 and DAPK site-specific hypermethylation and outcome in surgically trated stage I and II non-small cell lung cancer patients. Int J Cancer 126: 1630-1639, 2010.
19. Muggerud AA, Rønneberg JA, Wärberg F, Botling J, Busato F, Jovanovic J, Solvang H, Bukholm I, Børresen-Dale AL, Kristensen VN, Sørlie T and Tost J: Frequent aberrant DNA methylation of ABCB1, FOXC1, PPP2R2B and PTEN in ductal carcinoma in situ and early invasive breast cancer. Breast Cancer Res 12: R3, 2010.
20. Orchard JA, Ibbotson RE, Davis Z, Wiestner A, Rosenwald A, Thomas PW, Hamblin TJ, Staudt LM and Oscier DG: ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet 363: 105-111, 2004. (Pubitemid 38068326)
21. Corcoran M, Parker A, Orchard J, Davis Z, Wirtz M, Schmitz OJ and Oscier D: ZAP-70 methylation status is associated with ZAP-70 expression status in chronic lymphocytic leukemia. Haematologica 90: 1078-1088, 2005. (Pubitemid 41323507)
22. WAF1 negatively regulates DNMT1 expression in mammalian cells. Biochem Biophys Res Commun. 382: 171-176, 2009.
23. Iwase H, Omoto Y, Iwata H, Toyama T, Hara Y, Ando Y, Ito Y, Fujii Y and Kobayashi S: DNA methylation analysis at distal and proximal promoter regions of the oestrogen receptor gene in breast cancers. Br J Cancer 80: 1982-1986, 1999.
24. Pfaffl MW, Horgan GW and Dempfle L: Relative expression software tool (REST©) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res 30: 1-10, 2002.
25. WAF1. Science 277: 1996-2000, 1997.
26. Thorstensen L, Lind GE, Lovig T, Diep CB, Meling GI, Rognum TO and Lothe RA: Genetic and epigenetic changes of components affecting the WNT pathway in colorectal carcinomas stratified by microsatellite instability. Neoplasia 7: 99-108, 2005.
27. Amin S, Parker A and Mann J: ZAP70 in chronic lymphocytic leukaemia. Int J Biochem Cell Biol 40: 1654-1658, 2008.
28. Ambrogio C, Martinengo C, Voena C, Tondat F, Riera L, di Celle PF, Inghirami G and Chiarle R: NPM-ALK oncogenic tyrosine kinase controls T-cell identity by transcriptional regulation and epigenetic silencing in lymphoma cells. Cancer Res 69: 8611-8619, 2009.
29. Stefanska B, Rudnicka K, Bednarek A and Fabianowska-Majewska K: Hypomethylation and induction of retinoic acid receptor beta 2 by concurrent action of adenosine analogues and natural compounds in breast cancer cells. Eur J Pharmacol 638: 47-53, 2010.
30. Lefebvre B, Brand C, Flajollet S and Lefebvre P: Down-regulation of the tumour suppressor gene retinoic acid receptor beta2 through the phosphoinisitide 3-kinase/Akt signaling pathway. Mol Endocrinol 20: 2109-2121, 2006.